Argo Biopharma, a clinical-stage biotechnology company advancing next-generation siRNA therapies, announced the appointment of Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer on March 2nd, 2026. Dr. Wang joins Argo from Barclays, where she served as Managing Director, senior research analyst of Small and Mid-Cap Biotechnology.

According to a company press release, Dr. Wang’s speciality lies in RNA therapies, cell and gene therapies, and emerging modalities in rare diseases and oncology. In addition to her eight-year stint with Barclays, Dr. Wang has also worked as a sell-side analyst at investment banks like Jefferies and Leerink Partners. She received her Ph.D in Molecular Biology from the State University of New York and conducted her post-doctoral training at the Rockefeller University; both programs focused on RNA research.

“I am thrilled to join Argo Biopharma at such an important stage of its development,” said Dr. Wang in the release. “I have followed the evolution of RNA therapies for decades, and I believe Argo has developed a compelling, innovative siRNA platform to support potentially differentiated best-in-class assets across a wide range of important indications. I look forward to partnering with the management team to help Argo Biopharma achieve its long-term goals of delivering transformative therapeutics to patients while creating value for shareholders.”

“We are excited to welcome Dr. Wang to our management team,” said Dr. Dongxu Shu, co-founder, Chairman of the Board, and CEO, Argo Biopharma, in the release. “Her deep knowledge of the genetic medicines landscape, expertise in biotechnology capital markets, and her reputation and strong relationships within the financial community and healthcare industry make her an invaluable addition as we continue advancing our pipeline and entering our next phase of growth. I look forward to working closely with Dr. Wang in her new role.”